Consistent with our results in vitro, everolimus significantly reduced the expression of phosphorylated S6 and increased the expression of phosphorylated AKT (Ser473) in obese and lean mice compared with the untreated mice, suggesting that everolimus inhibited tumor growth through the mTORC1 pathway in vivo (p < 0.05). This evidence concerns the gene AKT1 and neoplasm.